SYDNEY, Oct. 31 /PRNewswire-FirstCall/ -- Ventracor Limited today announced a senior management appointment to further accelerate its global clinical trials and regulatory approval timelines in US and European markets.
Ventracor Chief Executive Officer, Colin Sutton PhD said: “We have appointed Tom Richards PhD as Vice President, Clinical and Regulatory Affairs as enrolment in our CE Mark Trial and US feasibility study approach completion in the first quarter of 2006.”
“Tom has successfully shepherded numerous medical device products through the European and US FDA regulatory process.
“He has an impressive array of experience in clinical and regulatory affairs gained at Teraklin AG (a multinational liver dialysis company), Karl Storz Endoscopy, Pharmacia Ophthalmics, and Staar Surgical,” Dr Sutton said.
Tom is the inventor of seven issued US patents, and has served as an advisor to several venture capital organisations and development stage companies.
He will be based in the US and report to Chief Operating Officer Peter Crosby.
About Ventracor
Ventracor is a global medical device company that has developed a blood pump, the VentrAssist(TM) left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssist(TM) to the global market in record time, and expects to obtain a significant share of the huge potential market.
For further information, please contact: Andrew Geddes Peter Crosby Manager, Investor Relations Chief Operating Officer Ventracor Limited Ventracor Inc + 61-2-9406-3086 +1-303-570-3327
Ventracor Limited
CONTACT: Andrew Geddes, Manager, Investor Relations of Ventracor Limited,+61-2-9406-3086, or Peter Crosby, Chief Operating Officer of Ventracor Inc,+1-303-570-3327
